Bayer agrees to buy Merck unit
Print Edition
GERMANY’S Bayer has agreed to buy Merck & Co’s non-prescription medicine and consumer care business for US$14.2 billion, gaining products such as Claritin allergy pills, Coppertone sun lotion and Dr Scholl’s footcare products.
Bayer said yesterday that the deal would make it the leader in over-the-counter products in North and Latin America. Bayer already has a major non-prescription division whose brands include Aleve pain reliever, Alka-Seltzer and One-A-Day vitamins. Bayer also makes prescription drugs, industrial materials and farm chemicals.
Marijn Dekkers, Bayer’s CEO, said the deal, which is subject to regulatory approval, “marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business.”
Leverkusen-based Bayer said it also has entered an agreement with Merck to cooperate on developing and selling drugs known as sGC modulators, which have potential for treating heart failure and pulmonary hypertension. Merck would initially pay Bayer US$1 billion, with further payments contingent on sales.
Merck CEO Kenneth Frazier said the sale was part of an effort to align the American company’s businesses with its strategy of being the premier research intensive drug company. Merck, which is headquartered in Whitehouse Station, New Jersey, said it would use the money from the sale to invest in business areas with the highest growth potential and augment its drug pipeline with “external assets.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
